Takeaways:

  • Syntara has raised A$10 million via a Placement and SPP, comprising A$8M institutional and A$2M retail.
  • Shares were issued at A$0.027 — a 15.6 per cent discount to the previous close.
  • The raise follows a positive FDA Type C meeting on amsulostat’s Phase 2b design for myelofibrosis.
  • Cash runway is extended to Q3 2027.
  • Funds support five 2026 clinical readouts, protocol finalisation and licensing discussions.

Syntara Limited (ASX:SNT), a clinical-stage Drug Development company targeting extracellular matrix dysfunction, has secured A$10 million in fresh Capital to advance its lead amsulostat program in myelofibrosis. The package comprises A$8 million through firm commitments under a two-Tranche institutional Placement and a non-underwritten share purchase plan (SPP) intended to raise an additional A$2 million.

Shares in the Capital raising were issued at A$0.027 each, representing a 15.6 per cent discount to Syntara’s last closing price on 24 April 2026. The discount is consistent with typical ASX small-cap clinical-stage placements, reflecting both the development risk profile and broader Liquidity dynamics in the segment.

FDA Type C meeting validates Phase 2b design

The Capital raise follows a recent positive Type C meeting outcome with the US FDA regarding the Phase 2b clinical trial design for amsulostat in myelofibrosis. The FDA supported Syntara’s proposed Phase 2b study design, providing guidance on the study’s details and the overall development pathway for amsulostat.

The Type C outcome is a meaningful regulatory milestone. Type C meetings provide an opportunity for sponsors to obtain FDA feedback on specific aspects of their development programs, and a positive outcome materially de-risks the design and statistical framework of the planned trial. For Syntara, the FDA validation also strengthens engagement with potential partners and licensors.

Amsulostat and the myelofibrosis opportunity

Amsulostat is Syntara’s lead asset, targeting myelofibrosis — a rare blood cancer characterised by bone marrow scarring, anemia and progressive disease burden. Existing therapies including JAK inhibitors provide symptomatic relief but do not address the underlying fibrotic process. Syntara’s mechanism, focused on extracellular matrix dysfunction, offers a differentiated approach.

The myelofibrosis market opportunity is substantial, with multiple large pharmaceutical companies actively pursuing pipeline Assets in the indication. A successful Phase 2b outcome would position Syntara as a potential partner or Acquisition candidate for established hematology players.

Use of proceeds and runway extension

Proceeds from the Capital raise are allocated across five key clinical trial readouts in 2026, Phase 2b preparatory work including protocol finalisation and CRO selection, and ongoing licensing discussions with potential commercial partners. The funding extends Syntara’s cash runway to Q3 2027, providing meaningful operational flexibility.

The five 2026 readouts span Syntara’s broader pipeline, including the Phase 2 myelodysplastic syndromes (MDS) trial designed to reduce transfusion burden. The cluster of readouts provides a consistent newsflow profile through 2026, supporting investor engagement.

Sector context: ASX hematology biotech

The ASX biotech cohort includes a number of companies targeting hematological conditions, with Syntara joined by names spanning anemia, thrombocytopenia and myeloproliferative disorders. The sector has historically attracted both retail and institutional interest given the high-value nature of hematology drugs and active M&A in the segment globally.

Syntara’s positioning at the Phase 2b stage, with FDA validation and a partnerable asset, places the company in a relatively differentiated cohort. The combination of a clear development pathway and partnering optionality supports the case for continued institutional engagement.